Technology CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology – BioSpace July 8, 2025 0 Comments Less than a minute 38 Views 3 months ago Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology BioSpace
